225Ac-OncoACP3 is a small molecule radiotracer with ultra high-affinity for Acid Phosphatase 3 (ACP3).
ACP3 is a phosphatase that is abundantly expressed in prostate cancer but undetectable in normal organs, with the exception of the healthy prostate. A side-by-side comparison between ACP3 and PSMA (currently considered the most validated marker of prostate cancer) has shown that ACP3 is more abundantly expressed in prostate cancer than PSMA, but cleaner in normal organs.
225Ac-OncoACP3 consists of a small organic ligand targeting ACP3 labelled with 225Actinium.
The product is being developed for the treatment of metastatic prostate cancer. 225Ac-OncoACP3 is partnered with RayzeBio, a Bristol Myers Squibb Company.
ONGOING CLINICAL TRIALS
- OncoFAP-68Ga has recently entered in a first-in-man imaging study in patients with advanced solid cancers
- Additional studies with OncoFAP-68Ga (Imaging) and OncoFAP-177Lu (Therapy) are about to start